The antacids drugs refer to the drugs that are used to neutralize stomach acid, and treat acid reflux, heartburn, and indigestion. Antacids are medications that counteract (neutralise) your stomach's acid to ease heartburn and indigestion. They are available without a prescription from pharmacies and stores and come in liquid or chewable tablet form. It includes drug classes such as proton pump inhibitors, H2 antagonists, surgical simulators, and acid neutralizers in the form of tablets, liquid, or powder. The main classes of antacids are proton pump inhibitors, H2 antagonists, acid neutralizers, and pro-motility agents. Proton-pump inhibitors are a type of drug that reduces stomach acid production significantly and for a long time. They accomplish this by blocking the H+/K+ ATPase proton pump in the stomach in an irreversible manner. The different types of formulations include tablets, liquids, powders, and others and are distributed through various channels such as hospital pharmacies, retail pharmacies, and others. The antacids market research report is one of a series of new reports from The Business Research Company that provides antacids market statistics, including antacids industry global market size, regional shares, competitors with an antacids market share, detailed antacids market segments, market trends, and opportunities, and any further data you may need to thrive in the antacids industry. This antacids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antacids market size will grow from $9.19 billion in 2022 to $9.56 billion in 2023 at a compound annual growth rate (CAGR) of 4.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global antacids market size is expected to grow to $10.65 billion in 2027 at a CAGR of 2.7%. Poor lifestyle choices resulting in a higher prevalence of acidity are an important driver for the growth of the antacids market. Poor lifestyle choices involve deskbound jobs, poor quality of sleep, and irregular dietary habits, which result in an increase in the acidity level of the stomach and lead to gastroesophageal reflux disease. According to the American College of Gastroenterology, around 60 million Americans suffer from gastroesophageal reflux disease. This drives the demand for antacids. The side effects related to antacids are a major restraint for the antacids market. Some of the common side effects of antacids include dose-dependent rebound hyperacidity and milk-alkali syndrome. Antacids containing aluminum hydroxide may also cause side effects such as constipation, aluminum-intoxication, osteomalacia, and hypophosphatemia. In addition, antacids when consumed with other acidic drugs might lead to absorption of both the drugs resulting in reduced efficiency of both the drugs. Mouth-melting antacid is an emerging trend in the antacid market. Antacids were available in tablet, liquid, and powder form until now; however, researchers have now come up with mouth-melting antacids which are made up of micro-mouth melting granules that easily melt in the mouth. These granules present in the antacids act in the form of effervescent. An example of a mouth-melting instant relief antacid is Sunpharma's 'Pepmelt', which integrates the effects of herbal constituents present in it with the contemporary mouth-melting technology. The manufacturers of antacids in the USA need to comply with CFR - Code of Federal Regulations Title 21 laid down by the FDA. According to these regulations, an over-the-counter (OTC) antacid product in a form suitable for oral administration is recognized as safe and effective only if it meets the conditions related to active ingredients established by the regulatory body. Major players in the antacids market are GlaxoSmithKline PLC., Pfizer Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., and AstraZeneca PLC, Boehringer Ingelheim GmbH, Sun Pharmaceuticals Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, and WellSpring Pharm. North America was the largest region in the antacids market in 2022. The Middle East is expected to be the fastest-growing region in the global antacids market. The regions covered in the global antacids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the antacids market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The antacids market consists of sales of Alka Seltzer, Maalox, Mylanta, Rolaids, Tums, and Pepto-Bismol. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antacids market is segmented - 1) Drug Class: Proton Pump Inhibitors, H2 Antagonist, Acid Neutralizers, Pro-Motility Agents 2) Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels 3) By Formulation Type: Tablet, Liquid, Powder, Other Formulation Types

Isothermal nucleic acid amplification technology (INAAT) is a technique that amplifies DNA samples. Isothermal nucleic acid amplification technologies are used to amplify DNA sequences from two different nucleic acid segments at a constant temperature. The main product types of isothermal nucleic acid amplification technology are instrument and reagent. A reagent is a material or compound that is added to a system to produce a chemical reaction or to determine whether or not a reaction occurred. The various technologies used are NASBA, and HAD, which are applied for blood screening, infectious disease diagnostics, and cancer. The various end users include hospitals, reference laboratories, and others. The isothermal nucleic acid amplification technology (INAAT) market research report is one of a series of new reports from The Business Research Company that provides isothermal nucleic acid amplification technology (INAAT) market statistics, including isothermal nucleic acid amplification technology (INAAT) industry global market size, regional shares, competitors with a isothermal nucleic acid amplification technology (INAAT) market share, detailed isothermal nucleic acid amplification technology (INAAT) market segments, market trends and opportunities, and any further data you may need to thrive in the isothermal nucleic acid amplification technology (INAAT) industry. This isothermal nucleic acid amplification technology (INAAT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global isothermal nucleic acid amplification technology (inaat) market will grow from $3.2 billion in 2022 to $3.53 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global isothermal nucleic acid amplification technology (inaat) market is expected to grow to $5.47 billion in 2027 at a CAGR of 11.6%. The incidence of infectious diseases such as H. influenzae, S. pneumonia (respiratory tract infections), N. gonorrhoeae, C. trachomatis (genital infections), and TB are increasing and require isothermal nucleic acid amplification technology (INAAT) to diagnose them. For instance, according to World Health Organization 17 million people lose their lives to infectious diseases every year. Another report by Centres for Disease Control show that number of diseases from mosquitoes, ticks and fleas like West Nile, Zika, Malaria and Lyme disease increased three times. Similarly, as per a survey done by NCBI, around 50% of the population in the United States (approx. 157 million) was suffering from at least one chronic disease in 2020. Increase in infectious or chronic disease drives the demand for diagnosing through isothermal nucleic acid amplification technology. The market for isothermal nucleic acid amplification technology is strictly regulated by stringent regulatory policies that govern the functioning, approvals and standards set for the manufacturers of this market. These regulations discourage companies to invest in new products for research and development or enter new markets. For example, the administration of US food and drugs (USFDA) requires multi-laboratory validation of a loop-mediating isothermal amplification which takes twice as much time as the Commission for European regulatory to review the process. Long regulatory procedures delay the scope for further study of the safety and efficacy of devices and affects the operating cycle of the vendors thereby adversely affecting the growth of the market. Nanostructures are being incorporated to in vitro diagnostics and in vitro rapid diagnostic tests (RDT) in order to improve existing tests and make them more effective or create innovative diagnostic test approaches that are incorporated in point-of-care applications. Nanostructures/nanotechnology uses nanoparticles to enhance the action of the drug in treatment and nanotechnology is the design, characterization, production, and application of devices, structures and systems by controlled manipulation of size and shape at the nanometer scale. For instance, a range of RDTs have been developed to diagnose syphilis such as AccuBioTech (Accu-Tell Rapid Syphilis Test), Alere, Inc. (Alere Determine), Alere/Standard Diagnostics (SD Syphilis 3.0), The Tulip Group/Qualpro (Syphicheck - WB), Cypress Diagnostics (Syphilis Rapid Test), and Omega Diagnostics (Visitect Syphilis). These RDTs allow patients to be diagnosed at the point-of-care (POC). The isothermal nucleic acid amplification technology market is regulated by government agencies such as European Medicines Agency (EMA), USFDA (the US food and drug ministration), and others. For instance, according to USFDA, each medical device is classified into three groups which is class 1, class 2 & class 3. Class 1 devices require less regulatory control and class 3 requires the most. However, devices which are not been marketed before as in the case of INAAT devices, will fall under class 3 devices as per the medical device amendment. Such devices require approval of a Pre-Market Application (PMA) under the federal law. Premarket approval (PMA) is the scientific and regulatory review process of the FDA to assess the safety and efficacy of medical devices of Class 3. In July 2021, Sapphiros, a KKR-backed platform focused on developing the next generation of diagnostic technologies, acquired Biocrucible Ltd. for an undisclosed amount. With this acquisition, Sapphiros aimed to develop market-leading consumer molecular diagnostics. Biocrucible Ltd., a biotechnology company based in the UK, is a pioneer in the acceleration and augmentation of biochemical kinetics through the use of its Molten TagsTM technology.  Major players in the market are Alere, Biomeriux, Qiagen, Becton, Dickinson & Company, Hologica, Lucigen, Quidel Corporation, New England Biolabs, Nugen, Ustar Biotechnologies, Thermo Fisher Scientific, BioHelix, Meridian Bioscience, New England Biolabs Inc., Novartis Diagnostics, Sharp Corp., Sony Corp., Panasonic, Toshiba Corp., Rohm, Philips Hologic-Gen-Probe, BetaLED, Avago technologies, and Grifols. North America was the largest region in the isothermal nucleic acid amplification technology (INAAT) market in 2022. Western Europe was the second largest region in the global isothermal nucleic acid amplification technology (INAAT) market. The regions covered in the global isothermal nucleic acid amplification technology (INAAT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The isothermal nucleic acid amplification technology (INAAT) market includes revenue earned by reaction systems and related services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global isothermal nucleic acid amplification technology (INAAT) market is segmented - 1) By Product: Instrument, Reagent 2) By End-User: Hospital, Reference Laboratories, Other End-Users 3) By Technology: NASBA, HAD 4) By Application: Blood Screening, Infectious Disease Diagnostics, Cancer

Gene therapy is used for correcting defective genes that are responsible for disease development. Nucleic acid-based therapeutics are used to treat genetic disorders and diseases for which there exists no permanent cure, such as anaemia, sickle cell, cystic fibrosis, and thalassemia. The main technologies in nucleic acid-based gene therapy are anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogues, ribozymes, aptamers, and others. The nucleoside analogues are a significant class of antiviral agents that are generally utilised in the therapy of human immunodeficiency virus (HIV) infection, hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV). The various applications include oncology, muscular dystrophy, muscular disorders, and rare diseases that are used by end-users such as hospitals and clinics and academic and research institutes. The nucleic acid-based gene therapy market research report is one of a series of new reports from The Business Research Company that provides nucleic acid-based gene therapy market statistics, including nucleic acid-based gene therapy industry global market size, regional shares, competitors with a nucleic acid-based gene therapy market share, detailed nucleic acid-based gene therapy market segments, market trends and opportunities, and any further data you may need to thrive in the nucleic acid-based gene therapy industry. This nucleic acid-based gene therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global nucleic acid based gene therapy market grew from $0.68 billion in 2022 to $0.75 billion in 2023 at a compound annual growth rate (CAGR) of 9.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The nucleic acid based gene therapy market is expected to grow from $1.06 billion in 2027 at a CAGR of 9.2%. Rising financial support by the government and the companies is projected to drive the demand for nucleic acid-based gene therapy. Nucleic acid therapeutics are analogs of naturally occurring acids or proteins responsible for genetic expression. The traditional therapies do not have any cure for the treatment of diseases such as cystic fibrosis, hemophilia, sickle cell anemia, thalassemia, and diabetes. Genetic profiling and molecular target identification form the backbone of these classes of drugs. Nucleic acid medication has greater potential for the treatment of these diseases, as they target the genetic basis of diseases and have a permanent cure. Rising financial support by the government and the companies dealing in the market for gene therapy is expected to contribute to increasing the demand for nucleic acid-based gene therapies. For instance, in August 2022, National Institute of Health (NIH) announced investment of $34 million annually for upcoming 5 years to develop HIV treatment research. The government support for gene therapies will contribute to the growth of the market. Stringent regulations imposed on gene therapies raise the price of gene therapies, which in turn hinders the demand for nucleic acid-based gene therapies. The excessive regulatory oversights create an expensive and elongated route for approval increasing the expenses. According to Foundation for Economic Education (FEE), unlike other drugs approved or regulated by the Food and Drug Administration (FDA), gene therapies are not only subject to the regulatory structure of the FDA, but also the Recombinant DNA Advisory Committee and Office of Biotechnology Activities. Also, as estimated by FEE, an approved gene therapy drug costs nearly $5.0 billion, which is five times higher than that of the average cost of FDA approval. The high cost of gene therapeutics drugs places them beyond the financial reach of the populace. This scenario is anticipated to restrain the market growth of the nucleic acid-based gene therapy market. The companies in the nucleic acid based gene therapy market are focusing on strategic partnerships and collaborations to help boost production. Major players are entering into partnership to expand their market and leverage each other’s resources. For example, in January 2022, Pfizer Inc., an American multinational pharmaceutical and biotechnology corporation, and Beam Therapeutics Inc., an American biotechnology company developing precision genetic medicines through base editing, announced an exclusive four-year research collaboration focused on in vivo base editing programs for three targets for rare genetic diseases of the liver, muscle and central nervous system. Similarly, in August 2022, Merck, an American multinational pharmaceutical company, and Orna Therapeutics, a US based biotechnology company pioneering a new investigational class of engineered circular RNA (oRNA) therapies, announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics in the areas of infectious disease and oncology. Major players in the nucleic acid-based gene therapy market are Celsion Corporation, Wave Life Sciences, Imugene, Caperna, Phylogica, Protagonist Therapeutics, Benitec Biopharma, EGEN, BioMedica, Transgene, and Copernicus Therapeutics. North America was the largest region in the nucleic acid-based gene therapy market in 2022. Western Europe was the second largest region in the global nucleic acid-based gene therapy market report.The regions covered in the global nucleic acid-based gene therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the nucleic acid-based gene therapy market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The nucleic acid based gene therapy market consists of sales of nucleic acid based gene therapy technologies such as anti-sense and anti-gene, short inhibitory sequences, gene transfer therapy, nucleoside analogs, ribozymes, aptamers, and other technologies. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part. The global nucleic acid based gene therapy market is segmented - 1) By Technology: Anti-Sence and Anti-Gene, Short Inhibitory Sequences, Gene Transfer Therapy, Nucleoside Analogs, Ribozymes, Aptamers, Other Technologies 2) By Application: Oncology, Muscular Dystrophy/ Muscular Disorders, Rare Diseases 3) By End User: Hospitals And Clinics, Academic And Research Institutes

The ursolic acid market consists of sales of ursolic acid and related-products by entities (organizations, sole traders, and partnerships) that manufacture ursolic acid that belongs to a member of the triterpene family of chemicals, which are found in both plants and mammals. Ursolic acid is a naturally occurring chemical molecule found in a wide range of plants, including rosemary and apples. It's presumed to contain anti-oxidant, anti-inflammatory, and cancer-fighting properties. The main types of ursolic acid include 25% ursolic acid, 50% ursolic acid, 90% ursolic acid, 98% ursolic acid and others. The 25% ursolic acid is extracted from different sources and standardized to 25% for a more reliable formulation and consistency. The various forms of ursolic acids are powdered form, capsules, liquid form and is used in pharmaceutical, food and beverages, cosmetics, nutraceuticals, and other industries. The ursolic acid market research report is one of a series of new reports from The Business Research Company that provides ursolic acid market statistics, including ursolic acid industry global market size, regional shares, competitors with a ursolic acid market share, detailed ursolic acid market segments, market trends and opportunities, and any further data you may need to thrive in the ursolic acid industry. This ursolic acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ursolic acid market size grew from $0.01 billion in 2022 to $0.01 billion in 2023 at a compound annual growth rate (CAGR) of 7.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The ursolic acid market size is expected to grow to $0.01 billion in 2027 at a CAGR of 7.1%. The increasing prevalence of cardiovascular diseases is expected to drive the growth of the ursolic acid market in the coming years. Ursolic acid has the potential to lower the heart rate, inhibit reproducing cell nuclear antigen expression in injured artery cells, and reduces lipid peroxide levels by scavenging free radicals. For instance, in October 2022, according to an article published by Centers for Disease Control and Prevention, a US-based public health agency, heart disease is the leading cause of death in the United States for men, women, and people of most racial and ethnic groups. In the United States, one person dies from cardiovascular disease every 34 seconds. In 2020, approximately 697,000 people in the United States died from heart disease, accounting for one out of every five deaths. Therefore, the increasing prevalence of cardiovascular diseases propels the growth of the ursolic acid market. Rapid growth in the utilization of ursolic acid in the manufacturing of various products in the cosmetic industry owing to spiked growth and demand for herbal products is expected to garner the growth of the market over coming years. Ursolic acid in cosmetic products is used as an anti-aging agent, anti-inflammatory, anti-wrinkle agent, and antioxidant. According to the Korea Customs Service statistics, In 2020, France ($433 million) was the largest exporter to Korea, followed by the United States ($337 million) and Japan ($161 million). The total export of K-beauty products and the balance of trade have increased by approximately 16% and 14%, respectively, over the previous year. In 2021, skincare cosmetics remained the most important import category, accounting for 34.17 percent, or $560 million, of total cosmetic imports. The next largest import categories were perfumes and scents, followed by haircare products. Thus, the increasing penetration of ursolic acid in the cosmetic industry drives the growth of the ursolic acid market. The side effects of ursolic acid are expected to hamper the growth of the ursolic acid market in the forecast period. Ursolic acid has been related to several negative effects According to research by Brain Wiz, ursolic acid may serve as an anti-fertility agent, reducing reproductive capacity in the short term. Although it has not been linked to long-term harm in the testes, animal studies indicate it may impair spermatogenesis. It may also affect sperm motility. The side effects of ursolic acid include nausea, stomach swelling, trace amounts of blood in the urine, increased sodium levels, and skin rash. Therefore, the side effects of ursolic acid hinder the growth of the ursolic acid market. Major players in the ursolic acid market are Sabinsa, Sami Labs, Changsha Staherb Natural Ingredients, Shaanxi Jintai Biological Engineering, Hunan NutraMax, Changsha E.K HERB, Xi an TonKing, Geneham Pharmaceutical, TCI Chemicals (India) Pvt. Ltd., MP Biomedicals, and Cayman Chemical Company. North America was the largest region in the ursolic acid market in 2022. Asia-Pacific was the second-largest market in ursolic acid market. The regions covered in the ursolic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ursolic acid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The ursolic acid market consists of sales of ursolic acid from various sources such as oreganp and holy basil. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ursolic acid market is segmented - 1) By Type: 25% Ursolic Acid, 50% Ursolic Acid, 90% Ursolic Acid, 98% Ursolic Acid, Other Types 2) By Form: Powdered Form, Capsules, Liquid Form 3) By End-Use: Pharmaceuticals, Food and Beverage, Cosmetics, Nutraceuticals, Other End-Uses

Food acidulants are acidic substances that are used as additives and contribute to reducing air, bacteria, fungi, and yeast spoilage, thereby extending the shelf life of food products. These additives further help to stabilize, preserve, maintain pH, and improve food properties. In addition, these additives can preserve food while acting as a gelling agent. The main types of acids in food acidulants are citric acid, lactic acid, acetic acid, phosphoric acid, malic acid, and others. Citric acid is an organic acid, that occurs naturally in many fruits, produced commercially by microbial fermentation of carbohydrate substrates. Citric acid has solubility, very low toxicity, chelating ability, and a pleasantly sour taste. The different forms include solid, and liquid, and are used in dairy and frozen products, bakery, the meat industry, beverages, confectionery, and others. The food acidulants market research report is one of a series of new reports from The Business Research Company that provides food acidulants market statistics, including food acidulants industry global market size, regional shares, competitors with a food acidulants market share, detailed food acidulants market segments, market trends and opportunities, and any further data you may need to thrive in the food acidulants industry. This food acidulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global food acidulants market size grew from $5.48 billion in 2022 to $6.06 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The food acidulants market size is expected to grow to $8.15 billion in 2027 at a CAGR of 7.7%. Increasing consumption of processed meat is expected to propel the growth of the food acidulants market going forward. Any meat that has been altered to increase its flavor or prolong its shelf life is considered processed meat. Food acidulants are used to increase the shelf life of processed meat, poultry, and fish products, as well as to inhibit the growth of disease-causing bacteria, improve flavor, and improve binding and retention capacity. For instance, according to the Organization for Economic Co-operation and Development - Food and Agriculture Organization (OECD-FAO) Agriculture, the growth in global meat consumption is projected to increase by 12% in between 2020 to 2029. In addition, global meat consumption is expected to reach 570 million tons by the year 2050. Therefore, the increasing consumption of processed meat is driving the growth of the food acidulant market. The rising consumer inclination towards various juices and liquid food is projected to fuel the growth of the food acidulants market in the coming years. Food-grade acidulants are used in juices and beverages to give them a tasty twist. Acidulants used in juices and beverages include fumaric acid, malic acid, and sugar alternatives. For example, according to the Hindustan Times, in the year 2020, 100 billion liters of liquid foods were consumed in India, less than 50% of that is packaged. Hence, rising consumer inclination towards the various juices and liquid food is driving the growth of the food acidulants market. In July 2021, KPS Capital Partners, a US-based investment company acquired a controlling stake in Tate & Lyle for $1.7 billion. This acquisition gives KPS Capital Partners operational control over the primary business of Tate & Lyle in North America, Latin America, in Almidones Mexicanos, and Dupont, Tate & Lyle’s joint venture bio-products company. Tate & Lyle is a UK-based company that offers nutritional sweeteners, soy protein, industrial starches, acidulants, and other corn products. Major players in the food acidulants market are ADM, Bartek Ingredients, Caremoli, Cargill, Hawkins Watts, Corbion, FBC Industries, Dairy Chem, Jungbunzlauer Suisse AG, Parry Enterprises India Limited, Purac biochem BV, Suntran Industrial Group Ltd., Weifang Ensign Industry Co., Ltd., Jones-Hamilton, Aditya Birla Chemicals, Celrich Products, and Fuerst Day Lawson. Asia-Pacific was the largest region in the food acidulants market in 2022. North America was the second-largest market in the food acidulants market. The regions covered in the food acidulants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the food acidulants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The food acidulants market consists of sales of citric acid, malic acid, lactic acid, phosphoric acid, acetic acid, and other food acidulants. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global food acidulants market is segmented - 1) By Type: Citric Acid, Lactic Acid, Acetic Acid, Phosphoric Acid, Malic Acid, Other Types 2) By Form: Solid, Liquid 3) By Application: Beverages, Dairy And Frozen products, Bakery, Meat Industry, Confectionery, Other Applications

The glutamic acid is used to build proteins to improve memory and focus, boost the immune system, support prostate health, detox the body, improve athletic performance, and also aid digestion. Glutamic acid refers to a form of amino acid that is converted to glutamate. This is a chemical that enables brain nerve cells to communicate with one another and send and receive information. It is necessary for the body's protein synthesis and plays an important function in the central nervous system. The amino acid is involved in so many processes in the body that it can prove to be beneficial in a variety of ways. The main types of glutamic acid are biosynthesis and industrial synthesis. Industrial organic synthesis products are employed as intermediates in a variety of chemical processes. The different sources include plant-based, and animal-based and are used in pharmaceuticals, food additives, animal and pet food, and other applications. The glutamic acid market research report is one of a series of new reports from The Business Research Company that provides glutamic acid market statistics, including global market size, regional shares, competitors with a glutamic acid market share, detailed glutamic acid market segments, market trends and opportunities, and any further data you may need to thrive in the glutamic acid industry. This glutamic acid market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global glutamic acid market size grew from $10.33 billion in 2022 to $11.37 billion in 2023 at a compound annual growth rate (CAGR) of 10.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The glutamic acid market size is expected to grow to $15.51 billion in 2027 at a CAGR of 8.1%. Consumer awareness toward healthy and nutritious foods is expected to propel the growth of the glutamic acid market going forward. Rising awareness about health issues helps prevent people from developing certain health issues. Food containing glutamic acid is beneficial to memory as well as body wellness due to its properties. As a result, increasing awareness related to health concerns and consumer attractiveness toward healthy and nutritious food increases the demand for the glutamic acid market. For instance, in 2020, according to the Global Wellness Institute, a US-based non-profit organization, the healthy eating, nutrition, and weight loss sector rose from $912 billion in 2019 to $946 billion in 2020. In addition, healthy-labeled foods and drinks had the largest sub-sector in 2020 ($680 billion), followed by vitamins & supplements ($137 billion) and weight loss products & services ($128 billion). Therefore, increasing consumer awareness towards healthy and nutritious food is driving the growth of the glutamic acid market. Strategic collaborations and partnerships have emerged as a key trend gaining popularity in the glutamic acid market. Major companies operating in the glutamic acid market are entering into partnerships and collaborations to sustain their business in the market. For instance, in March 2021, Evonik, a German-based company operating in glutamic acid, entered into a supply agreement with Cassava Sciences, a US-based biotechnology company. Through this agreement, Evonik would supply clinical-grade quantities similar to Cassava Sciences, which is a drug candidate for the treatment of Alzheimer's disease. Further, in September 2020, Evonik, a German-based company operating in glutamic acid, entered into a strategic partnership with Unilever, a UK-based producer of consumer goods. Through this collaboration, Evonik’s biotech expertise would act as a central pillar for Unilever’s Clean Future initiative. In October 2020, American Vanguard Corporation (AVC), a US-based agrochemical company, acquired the Agrinos Group of companies for an undisclosed amount. Through this acquisition, Agrinos's portfolio is expected to complement AVC's Green Plant liquid nutrition products, which have enjoyed successful growth in the Central American market. Agrinos is a US-based full-service biological input provider that manufactures glutamic acids. Major players in the glutamic acid market are AMINO GmbH, Evonik Industries AG, Fufeng Group, Hefei TNJ Chemical Industry Co.Ltd., Kyowa Hakko Bio Co. Ltd., Medinex Laboratories Pvt. Ltd., Sichuan Tongsheng Amino acid Co. Ltd., Wuhan Amino Acid Bio-Chemical Co. Ltd., Global Bio-chem Technology Group Company Limited, Ningxia Yipin Biological Technology Co. Ltd., Akzo Nobel N.V., Iris Biotech GmbH, Ottokemi, and Luojiang Chenming Biological Products Co. Ltd. North America was the largest region in the glutamic acid market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glutamic acid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the glutamic acid market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The glutamic acid market consists of sales of glutamic acid that is used in the body to build proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global glutamic acid market is segmented - 1) By Product: Biosynthesis, Industrial Synthesis 2) By Source: Plant-Based, Animal Based 3) By Application: Pharmaceutical, Food Additives, Animal and Pet Food, Other Applications

Fatty acids are carboxylic acids that act as energy for muscles, the heart, and other organs as building blocks for fats in the human body and also as an agent that manages inflammation in the body. Fatty acids comprise a straight chain of an even number of carbon atoms with hydrogen atoms along the length of the chain and at one end of the chain and a carboxyl group (COOH) at the other end. The main product types of fatty acids are unsaturated fatty acids and saturated fatty acids. Saturated fatty acids (SFA) are fatty acids that contain no double bonds and have the formula R-COOH. The R-group is a straight-chain hydrocarbon of the form CH3(CH2)n with varying lengths, ranging from short-chain lengths (volatile liquids) to chain lengths of 30 or more carbon atoms (waxy solids). The forms are oil, capsule, syrup, powder. The sources are vegetable oils, marine oils, nuts and seeds, soy and soy products. End-user industries include household, cosmetics and personal care, soap and detergent, oilfield, rubber and plastic, lubricants, and others. The fatty acids market research report is one of a series of new reports from The Business Research Company that provides fatty acids market statistics, including fatty acids industry global market size, regional shares, competitors with a fatty acids market share, detailed fatty acids market segments, market trends and opportunities, and any further data you may need to thrive in the fatty acids industry. This fatty acids market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fatty acids market size will grow from $82.09 billion in 2022 to $89.7 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global fatty acids market size is expected to grow from $123.61 billion in 2027 at a CAGR of 8.3%. The fatty acids market is being driven by the rising demand for cosmetics and personal care products. Fatty acids are the emollients and emulsifiers in the cosmetics industry, used to replenish and soothe the skin. It is used as an ingredient in a variety of skincare products such as creams, lotions, shampoos, and lipsticks. Esters of fatty acids such as triglycerides, phospholipids, and cholesterol esters are commonly used in cosmetics as skin hydrants and thickeners. According to Coty, a French beauty company, the beauty market has been constantly growing at 3% to 5% every year. Coty also forecasts that its net revenue will grow by 6% to 8% each year through 2025. The rising demand for cosmetics and personal care products increased the demand for fatty acids, thus driving the market during the period. Biological effects due to fatty acid deficiency are a major restraint in the fatty acid market. Biological effects such as blood pressure, stroke, coronary artery disease, inflammation, and various other diseases may occur due to insufficient intake of fatty acids such as alpha-linolenic acid (ALA) and gamma-linolenic acid (GLA). These two fatty acids are necessary and must be included in the diet. Fatty acid deficiency is most commonly observed in infants. The deficiency results in scaly dermatitis, alopecia, thrombocytopenia, and intellectual disability in children. In the US, according to the National Institutes of Health, deficiency of essential fatty acids such as omega-3s and omega-6s can lead to rough, scaly skin and dermatitis. Due to rising awareness regarding health, omega fatty acid supplements are increasingly being used. Omega fatty acids are present extensively in fish oils and are vital ingredients for the human body. Omega-3 supplements can help relieve rheumatoid arthritis symptoms and can also be used as dietary supplements or medicinal supplements. The use of Omega-3 fatty acids and Omega-6 fatty acids helps to combat diseases and improve cardiovascular health, promote healthy metabolism, reduce pain and inflammation in joints, increase optimal brain function, etc. According to the World Health Organization (WHO), 17.9 million people in the world die every year due to cardiovascular diseases. Therefore, rising awareness regarding health issues, especially for heart diseases, is expected to drive the market for fatty acids. In July 2020, Croda, a UK-based specialty chemicals company, acquired Avanti Polar Lipids for an undisclosed amount. This acquisition of Avanti combines with Croda to expand life sciences products, pharmaceutical services, and cGMP production capabilities for biotechnology, pharmaceutical, and life science research customers globally. Avanti Polar Lipids is a US-based biotechnology company. Major players in the fatty acids market are BASF SE, FMC Corporation, The Dow Chemical Company, Koninklijke Dsm Nv, Enzymotec Ltd., Croda International PLC., Omega Protein Corporation, Aker Biomarine As, Polaris Nutritional Lipids, and Cargill, Incorporated. Asia-Pacific was the largest region in the fatty acids market in 2022. North America was the second-largest region in the global fatty acids market. The regions covered in the global fatty acids market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the fatty acids market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, the UK, the USA, and Australia. The fatty acids market consists of the sales of monounsaturated, polyunsaturated, and trans fats. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fatty acids market is segmented - 1) By Product Type: Unsaturated Fatty Acids, Saturated Fatty Acids 2) By Form: Oil, Capsule, Syrup, Powder 3) By Source: Vegetable Oils, Marine, Nuts and Seeds, Soy and Soy Products 4) By End User Industry: Household, Cosmetics, and Personal Care, Soap and Detergent, Oilfield, Rubber and Plastic, Lubricants, Other End-user Industries

Nucleic Acid Based Gene Therapy Market Definition

The nucleic acid-based gene therapy market consists of sales of nucleic acid-based gene therapy products and services. Gene therapy is used for correcting defective genes that are responsible for disease development. Nucleic acid therapies are highly specific and long-lasting compared to the conventional therapies which are generally transient and have low specificity. Nucleic acid-based therapy either uses unmodified DNA or RNA or closely related compounds. Nucleic acid-based therapeutics are used to treat genetic disorders and diseases for which there is no permanent cure such as anemia, sickle cell, cystic fibrosis, diabetes, and thalassemia. Gene therapy is a technique, which modifies genes to treat or prevent diseases. Genes are the basic physical and functional unit of heredity, received from one’s parents. Genes act as a code for the creation of all proteins in a living organism. Gene therapy seeks to manipulate a patient’s cells to alter the biological property of cells for the treatment of an inherited or acquired disease. It works by several mechanisms, including replacing a disease-causing gene with a healthy copy of the gene, inactivating an ill-functioning disease-causing gene, or introducing a modified gene into the body to treat diseases.